This week, LTR Pharma announced the key findings of its pivotal clinical study of SpontanÒ, demonstrating that the nasal spray is absorbed 470% faster than oral tablets.
Executive Chairman, Lee Rodne, recently spoke with @ausbiz anchor Nadine Blayney about the significance of these findings, the Company’s plans to target the US market, and the importance of the Australian market for early prescriptions.
“Australia is really important for us as our home market. We’re getting early prescriptions in the Australian market, which means a great deal to us, because it’s giving us that real world clinical data that we can use in our FDA processes, plus in our commercial partnering programs.”